PMID- 38041950
OWN - NLM
STAT- MEDLINE
DCOM- 20240222
LR  - 20240222
IS  - 1943-569X (Electronic)
IS  - 0003-1488 (Linking)
VI  - 262
IP  - 3
DP  - 2024 Mar 1
TI  - Veterinary oncologists and pet owners differ in their perceptions of 
      chemotherapy-related adverse events in cancer-bearing dogs.
PG  - 334-342
LID - 10.2460/javma.23.09.0496 [doi]
AB  - OBJECTIVE: Chemotherapy is widely used in veterinary oncology but carries real 
      and perceived risks of adverse events (AEs). Human cancer patients perceive AEs 
      from chemotherapy as more severe than do their attending physicians. It is 
      currently unknown whether this discrepancy exists in veterinary oncology. This 
      survey study's aim was to assess differences in the ways that pet owners and 
      veterinary oncologists perceive chemotherapy-related AEs. We hypothesized that 
      veterinary oncologists would accept higher grade AEs and tolerate a greater risk 
      of AEs of any grade than pet owners. SAMPLE: 152 pet owners and 111 veterinary 
      oncologists. METHODS: Separate surveys were derived for pet owners and veterinary 
      oncologists. Respondents were asked to define maximally acceptable AE scores and 
      risks of AEs given 3 hypothetical outcomes of treatment: (1) cure, (2) extension 
      of life, and (3) improved quality of life. Statistical tests were used to compare 
      responses between groups. RESULTS: Veterinary oncologists accepted higher grade 
      AEs if the hypothetical goal of chemotherapy was cancer cure (P = .003) or 
      extension of life (P = .026), but owners accepted higher grade AEs if the goal of 
      chemotherapy was to improve quality of life (P = .002). Owners accepted greater 
      risk of moderate (P < .0001) or serious (P < .0001) AEs across the 3 treatment 
      outcomes. CLINICAL RELEVANCE: This was the first study to assess how pet owners 
      and veterinary oncologists differ in their perception of chemotherapy-related 
      AEs. These initial results may help to frame discussions with pet owners on the 
      expectations of chemotherapy.
FAU - Leonardi, Abby J
AU  - Leonardi AJ
AD  - 1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, 
      Purdue University, West Lafayette, IN.
FAU - Fulkerson, Christopher M
AU  - Fulkerson CM
AD  - 1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, 
      Purdue University, West Lafayette, IN.
AD  - 2Institute for Cancer Research, Purdue University, West Lafayette, IN.
FAU - Shields, Cleveland G
AU  - Shields CG
AD  - 3Department of Human Development and Family Science, College of Health and Human 
      Sciences, Purdue University, West Lafayette, IN.
FAU - Childress, Michael O
AU  - Childress MO
AD  - 1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, 
      Purdue University, West Lafayette, IN.
AD  - 2Institute for Cancer Research, Purdue University, West Lafayette, IN.
LA  - eng
PT  - Journal Article
DEP - 20231201
PL  - United States
TA  - J Am Vet Med Assoc
JT  - Journal of the American Veterinary Medical Association
JID - 7503067
SB  - IM
MH  - Humans
MH  - Animals
MH  - Dogs
MH  - Quality of Life
MH  - Ownership
MH  - Surveys and Questionnaires
MH  - Health Personnel
MH  - *Neoplasms/drug therapy/veterinary
MH  - *Dog Diseases/chemically induced/drug therapy
OTO - NOTNLM
OT  - oncology
OT  - patient-reported outcomes
OT  - quality of life
OT  - risk tolerance
OT  - side effects
EDAT- 2023/12/03 00:42
MHDA- 2024/02/22 06:43
CRDT- 2023/12/02 18:05
PHST- 2023/09/05 00:00 [received]
PHST- 2023/11/01 00:00 [accepted]
PHST- 2024/02/22 06:43 [medline]
PHST- 2023/12/03 00:42 [pubmed]
PHST- 2023/12/02 18:05 [entrez]
AID - 10.2460/javma.23.09.0496 [doi]
PST - epublish
SO  - J Am Vet Med Assoc. 2023 Dec 1;262(3):334-342. doi: 10.2460/javma.23.09.0496. 
      Print 2024 Mar 1.